The role of SGLT2 inhibitors beyond glucose-lowering to cardio-renal protection

The role of SGLT2 inhibitors beyond glucose-lowering to cardio-renal protection

People with type 2 diabetes mellitus (T2DM) are at high risk of developing cardiovascular disease (CVD) and kidney disease. This enhanced cardio-renal risk persists despite improvements in care and treatments over the last 20 years. Intensive glucose control alone does not substantially reduce the r...

Full beskrivning

Bibliografiska uppgifter
Huvudupphovsman:	J. Karalliedde
Materialtyp:	Artikel
Språk:	Russian
Publicerad:	«FIRMA «SILICEA» LLC 2021-04-01
Serie:	Российский кардиологический журнал
Ämnen:	cardiovascular disease hospitalization for heart failure end stage kidney disease
Länkar:	https://russjcardiol.elpub.ru/jour/article/view/4323

Liknande verk

Retrospective analysis of SGLT2 inhibitors in heart failure with preserved ejection fraction
av: John S. Clemmer, et al.
Publicerad: (2023-06-01)

Editorial: Recent advancement of the cardio-renal protective effects of SGLT2 inhibitors in people with and without diabetes
av: Satoru Kuriyama, et al.
Publicerad: (2023-10-01)

Dramatic disease regression in a case of HFrEF with end‐stage renal failure treated with sacubitril/valsartan and SGLT2i
av: Massimo Mapelli, et al.
Publicerad: (2023-06-01)

Assessment of Relationship between Galectin-3 and Biochemical Parameters in Peritoneal Dialysis Patients with Left Ventricular Hypertrophy
av: Sultan Alouffi, et al.
Publicerad: (2020-08-01)

Myocardial Cytoskeletal Adaptations in Advanced Kidney Disease
av: Arvin Halim, et al.
Publicerad: (2022-03-01)

Efficacy and Safety of the Use of SGLT2 Inhibitors in Patients on Incremental Hemodialysis: Maximizing Residual Renal Function, Is There a Role for SGLT2 Inhibitors?
av: José C. De La Flor, et al.
Publicerad: (2023-07-01)

Risk prediction modeling for cardiorenal clinical outcomes in patients with non-diabetic CKD using US nationwide real-world data
av: Christoph Wanner, et al.
Publicerad: (2025-01-01)

Exploring SGLT-2 Inhibitors: Benefits beyond the Glucose-Lowering Effect—What Is New in 2023?
av: Clipper F. Young, et al.
Publicerad: (2023-09-01)

Incidence of end‐stage renal disease after heart transplantation and effect of its treatment on survival
av: Stefan Roest, et al.
Publicerad: (2020-04-01)

Major cardiovascular events and associated factors among routine hemodialysis patients with end-stage renal disease at tertiary care hospital in Somalia
av: Mohamed Farah Yusuf Mohamud, et al.
Publicerad: (2023-05-01)

Estimating the population-level impacts of improved uptake of SGLT2 inhibitors in patients with chronic kidney disease: a cross-sectional observational study using routinely collected Australian primary care dataResearch in context
av: Brendon L. Neuen, et al.
Publicerad: (2024-02-01)

SGLT2 Inhibitors: Nephroprotective Efficacy and Side Effects
av: Carlo Garofalo, et al.
Publicerad: (2019-06-01)

ISCHEMIC HEART DISEASE AND RENAL DYSFUNCTION
av: F. I. Belyalov
Publicerad: (2017-07-01)

SGLT2 inhibitors: Beyond glycemic control
av: Irtiza Hasan, et al.
Publicerad: (2024-03-01)

SGLT2 Inhibitors: The Next Blockbuster Multifaceted Drug?
av: Jonathan C. H. Chan, et al.
Publicerad: (2023-02-01)

Cardiovascular protection by SGLT2 inhibitors – Do anti-inflammatory mechanisms play a role?
av: Asmaa Elrakaybi, et al.
Publicerad: (2022-10-01)

Management of Cardiovascular Diseases in Chronic Hemodialysis Patients
av: Zhen Zhang, et al.
Publicerad: (2023-06-01)

Incident heart failure and the subsequent risk of progression to end stage kidney disease in individuals with type 2 diabetes
av: Sylvia Liu, et al.
Publicerad: (2024-06-01)

Evolution of sodium-glucose co-transporter 2 inhibitors from a glucose-lowering drug to a pivotal therapeutic agent for cardio-renal-metabolic syndrome
av: Hiroki Akiyama, et al.
Publicerad: (2023-01-01)

Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor: In the heart of the problem
av: Natalia G. Vallianou, et al.
Publicerad: (2021-06-01)

Real-life underuse of SGLT2 inhibitors for patients with type 2 diabetes at high cardiorenal risk
av: André J. Scheen
Publicerad: (2024-01-01)

SGLT2i: beyond the glucose-lowering effect
av: Lihua Ni, et al.
Publicerad: (2020-06-01)

Exploring the Cardiorenal Benefits of SGLT2i: A Comprehensive Review
av: Angelica Cersosimo, et al.
Publicerad: (2024-10-01)

New insights into the cardio-renal benefits of SGLT2 inhibitors and the coordinated role of miR-30 family
av: Abdellatif El Khayari, et al.
Publicerad: (2024-11-01)

Dipyridamole treatment is associated with improved renal outcome and patient survival in advanced chronic kidney disease
av: Chi-Chih Hung, et al.
Publicerad: (2014-12-01)

Indirect comparison of SGLT2 inhibitors in patients with established heart failure: evidence based on Bayesian methods
av: Hai‐Bin Chen, et al.
Publicerad: (2023-04-01)

Hospitalization Trajectories and Risks of ESKD and Death in Individuals With CKD
av: Anand Srivastava, et al.
Publicerad: (2021-06-01)

Predictors of cardiovascular disease in peritoneal dialysis patients: A Prospective longitudinal cohort study
av: I. Shifris, et al.
Publicerad: (2022-11-01)

Pathophysiology of the cardio-renal syndromes types 1–5: An uptodate
av: L. Di Lullo, et al.
Publicerad: (2017-03-01)

Impact of end stage renal disease on the clinical outcomes of diabetics admitted for heart failure: Analysis of national inpatient sample
av: Muhammad Usman Almani, et al.
Publicerad: (2023-03-01)

The expanding role of SGLT2 inhibitors beyond glucose-lowering to cardiorenal protection
av: Emily Brown, et al.
Publicerad: (2021-01-01)

Incident heart failure and the subsequent risk of progression to end stage kidney disease in individuals with type 2 diabetes
av: Liu, Sylvia, et al.
Publicerad: (2024)

Cardio-renal syndrome [version 1; referees: 3 approved]
av: Joseph Gnanaraj, et al.
Publicerad: (2016-08-01)

Editorial: CaRe Me: improving the cardio-renal-metabolic care of patients through clinical and translational research
av: José Jesús Broseta, et al.
Publicerad: (2024-07-01)

Association of diabetes-related kidney disease with cardiovascular and non-cardiovascular outcomes: a retrospective cohort study
av: James B. Wetmore, et al.
Publicerad: (2019-08-01)

Editorial: Clinical prospective of SGLT2 inhibitors in atherosclerosis
av: Annalisa Capuano, et al.
Publicerad: (2022-11-01)

Impact of Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Renal Function in Patient with Heart Failure
av: Teruhiko Imamura, et al.
Publicerad: (2021-12-01)

A Call for a New Paradigm for Diabetes Care in the Era of Sodium–Glucose Cotransporter 2 Inhibitors (SGLT2i)
av: Sun H. Kim, et al.
Publicerad: (2020-07-01)

The role of sodium-glucose co-transporter (SGLT)-2 inhibitors in heart failure management and implications for the kidneys
av: Eirini Lioudaki, et al.
Publicerad: (2022-03-01)

Retinopathy and Risk of Kidney Disease in Persons With DiabetesPlain-Language Summary
av: Jingyao Hong, et al.
Publicerad: (2021-09-01)